Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Orexo

1.00 SEK-0.60 %19/11 17:29
Less than 1K followers

ORX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-0.60 %
-72.28 %
-88.99 %
-91.51 %
-94.70 %
-94.10 %
-89.51 %
-95.56 %
-98.23 %

Orexo is a Swedish pharmaceutical company that develops improved medicines based on proprietary formulation technologies and with a focus on meeting major medical needs. In the US market, Orexo commercializes treatments for patients suffering from opioid addiction. Products targeting other therapeutic areas are developed and commercialized worldwide through partners.

Read more
Market cap
353.3M SEK
Turnover
666.67K SEK
Revenue
26M
EBIT %
-1,356.54 %
P/E
0.05
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
4/2
2027

Annual report '26

27/4
2027

Interim report Q1'27

14/6
2027

General meeting '27

Regulatory press release2026-11-19 09:41

Finansinspektionen: Flaggningsmeddelande i Orexo AB

Orexo
Regulatory press release2026-11-16 17:42

Finansinspektionen: Flaggningsmeddelande i Orexo AB

Orexo
Regulatory press release2026-11-16 14:35

Finansinspektionen: Flaggningsmeddelande i Orexo AB

Orexo

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
Followings and notifications on followed companies
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release2026-11-16 09:38

Finansinspektionen: Flaggningsmeddelande i Orexo AB

Orexo
Press release2026-11-13 08:00

Nya data för OX640 presenterade vid ACAAI visar att kliniskt relevanta adrenalinnivåer uppnås snabbt samt att produkten har förbättrad stabilitet

Orexo
Press release2026-11-13 08:00

New OX640 Data Presented at ACAAI Demonstrate Rapid Achievement of Clinically Meaningful Epinephrine Levels and Enhanced Stability

Orexo
Press release2026-11-11 08:00

Orexo och SVF Vaccines samarbetar för att undersöka formulering av LNP-mRNA-vacciner med AmorphOX®

Orexo
Press release2026-11-11 08:00

Orexo and SVF Vaccines collaborate to explore AmorphOX® formulation of LNP-mRNA Vaccines

Orexo
Regulatory press release2026-11-11 08:00

Orexo offentliggör informationsdokument avseende företrädesemission

Orexo
Regulatory press release2026-11-11 08:00

Orexo publishes disclosure document regarding rights issue

Orexo
Press release2026-11-10 08:00

Orexo presenterar ytterligare data om OX640, ett nytt adrenalinpulver för nasal administrering, vid två muntliga presentationer på ACAAI 2026

Orexo
Press release2026-11-10 08:00

Orexo to present additional data on OX640, a novel nasal epinephrine powder, in two oral presentations at ACAAI 2026

Orexo
Regulatory press release2026-11-06 10:25

Kommuniké från Orexo AB:s extra bolagsstämma den 6 november 2026

Orexo
Regulatory press release2026-11-06 10:25

Report from Orexo AB’s extraordinary general meeting, 6 November 2026

Orexo
Regulatory press release2026-11-03 13:36

Finansinspektionen: Flaggningsmeddelande i Orexo AB

Orexo
Regulatory press release2026-11-02 22:00

Orexo offentliggör slutliga villkor för företrädesemissionen om cirka 253 MSEK

Orexo
Regulatory press release2026-11-02 22:00

Orexo announces final terms for the rights issue of approximately 253 MSEK

Orexo
Press release2026-10-29 11:00

Orexo meddelar att FDA har accepterat den återinlämnade registreringsansökan för IZIPRY™ för granskning

Orexo
Press release2026-10-29 11:00

Orexo announces FDA acceptance of IZIPRY™ NDA resubmission for review

Orexo
Regulatory press release2026-10-22 16:18

Finansinspektionen: Flaggningsmeddelande i Orexo AB

Orexo